RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer Share Article Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies “What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies.” – Jon A. Rowley, PhD, founder and chief product officer, RoosterBio FREDERICK, MD. (PRWEB) OCTOBER 05, 2021 RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) bioprocess systems for cell and gene therapy product developers, today announced Timothy M. Kelly, PhD, has joined the company as Chief Executive Officer and as a member of the Board of Directors. Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies in the U.S. and Europe. “We are excited to welcome Tim to the RoosterBio team! Tim brings extensive leadership experience and a proven track record growing small companies into highly sustainable businesses. What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies,” said…
With a goal of expanding manufacturing capabilities to meet the growing demands of cell and gene therapy production, The Center for Breakthrough Medicines (CBM) promoted Chief Operating Officer Joerg Ahlgrimm to the role of Chief Executive Officer. Ahlgrimm joined CBM last year after serving as Head of Global Operations Pharma Biotech and Nutrition at Lonza. CBM, located within the Discovery Labs campus in suburban Philadelphia, is a quickly growing contract development and manufacturing organization that aims to provide pre-clinical through commercial manufacturing capabilities for client companies. CBM’s offerings include process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.
TEDCO’s Tammi Thomas Selected for Leadership Greater Washington 2022 Cohort. Established over 35 years ago, LGW has developed nearly 2,000 executive-level leaders from the District of Columbia, Virginia, and Suburban Maryland through its flagship offering, the Signature Program. It’s an intensive ten-month program that exposes professionals to regional civic issues through education, connection, and knowledge sharing. With the purpose to leverage collective knowledge and resources to make the Greater Washington region a more dynamic and collaborative community.
Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore
BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.
Arcellx, a privately held clinical-stage biopharmaceutical company, announced the addition of Kate Aiken as Chief People Officer. Kate is an accomplished human resources business leader who brings more than 20 years of cross-industry experience, building and managing high caliber HR organizations and partnering with business leaders to support the growth of industry leading companies.
John Gustin Joins CSSi LifeSciences As Associate Director of Commercial Development. His role will involve managing clients’ projects, which include regulatory filings and commercial planning. Also, he will be connecting clients with strategic partners, such as investors or distributors. Internally, he will be building out CSSi’s project management processes to assist in the scaling of the company
Mr. Semerjian is a global biopharmaceutical veteran. Over the last 25 years, he acquired extensive US, European and international commercialization experience having led multiple successful hematology/oncology product launches, including preparation for the launch of midostaurin in AML.